如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京昭衍新藥研究中心股份有限公司 呈交日期： 2024年9月20日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 603127 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（ ...

公司名稱： 北京昭衍新藥研究中心股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2024年9月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 603127 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份） ...

Investment Rating - The report maintains an "Outperform" rating for Zhaoyan New Drug (603127 SH) [2][4] Core Views - Short-term performance pressure in H1 2024, with signs of recovery in Q2 [2][5] - Revenue in H1 2024 was RMB 849 million (-16 1%), with net profit attributable to shareholders of -RMB 170 million (-287 3%) [2] - Q2 revenue was RMB 525 million (-18 4%), a 61 5% increase from Q1, with net profit turning positive at RMB 102 million [2][5] - The company's core non-clinical business maintains a leading industry position, with continuous innovation in technology platforms [2][11] - Clinical services show strong growth momentum, particularly in early-stage clinical research and gene therapy [2][12] Financial Performance - H1 2024 gross margin was 30 4% (-14 0pp), and net margin was -20 3% (-29 1pp) [9] - Operating expenses ratio increased to 18 4% (+3 8pp) in H1 2024 [9] - The company's order backlog was RMB 2 9 billion (-25 1%) as of H1 2024, with new orders of RMB 900 million (-30 8%) [2][10] - Q2 new orders were RMB 500 million, a 20% increase from Q1 [2][10] Business Development - The company's Beijing and Suzhou facilities passed FDA GLP inspections for the fifth time, enhancing quality systems [11] - Expanded disease models and drug evaluation technologies in ophthalmology, otology, and CNS fields [11] - Strengthened analytical testing platforms for small and large molecule drugs [11] - Clinical CRO services demonstrated advantages in Phase I and IIT studies, reducing client R&D costs [12] - Clinical testing services showed growth, particularly in gene therapy, supporting multiple innovative drugs in critical clinical stages [12] Profit Forecast - Revenue for 2024/2025/2026 is expected to be RMB 2 042/2 268/2 522 million, with a YoY growth of -14 1%/+11 1%/+11 2% [13][16] - Net profit for 2024/2025/2026 is expected to be RMB 91/300/335 million, with a YoY growth of -77 1%/+229 7%/+11 6% [13][16] - Gross margin for 2024/2025/2026 is forecasted at 27 8%/28 7%/29 6%, lower than 2023 levels [13][16] Valuation Metrics - PE ratios for 2024/2025/2026 are 113 8x/34 5x/30 9x [3][16] - ROE for 2024/2025/2026 is expected to be 1 1%/3 5%/3 8% [3][16] - EV/EBITDA for 2024/2025/2026 is 53 2x/39 3x/32 4x [3][16]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 有關生仝智能及熠昭（北 京）醫藥的資料 生仝智能剩餘約18.43%股 份 由 以 下 人 士 最 終 擁 有：(a)約9.54%預留給生仝智能 的 員 工 購 股 權 計 劃；(b)約0.2%由馮宇靜女士（馮 女 士 的 親 戚）擁 有；及(c)約8.69% 由八名個人（均 為 獨 立 第 三 方，且 彼 等 各 自 持 有 的 生 仝 智 能 股 份 均 少 於5%）擁 有。 茲提述北京昭衍新藥研究中心股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱 為「本集團」）日期為2024年8月30日的公告（「該公告」），內 容 有 關2024年北京昭衍 生 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京昭衍新藥研究中心股份有限公司 呈交日期： 2024年9月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 603127 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 849,357 thousand, a decrease of 16.1% compared to RMB 1,012,077 thousand for the same period in 2023[2] - Gross profit for the same period was RMB 211,301 thousand, down 52.8% from RMB 447,799 thousand in 2023[2] - The net loss attributable to equity shareholders for the six months ended June 30, 2024, was RMB (169,742) thousand, compared to a profit of RMB 90,627 thousand in 2023, representing a decline of 287.3%[2] - Total comprehensive loss for the period was RMB (169,213) thousand, compared to a comprehensive income of RMB 102,760 thousand in the previous year[4] - Basic and diluted loss per share for the period was RMB (0.23), compared to earnings per share of RMB 0.12 in the same period last year[4] - The company reported a significant increase in research and development expenses, totaling RMB 47,840 thousand for the period, compared to RMB 56,933 thousand in 2023[3] - Total revenue from external customers for the six months ended June 30, 2024, was RMB 849,357,000, a decrease from RMB 1,012,077,000 for the same period in 2023, representing a decline of approximately 16.1%[20] - Reported segment gross profit for the six months ended June 30, 2024, was RMB 211,301,000, down from RMB 447,799,000 in the same period of 2023, indicating a decrease of about 52.8%[18] - The gross profit margin for the six months ended June 30, 2024, was approximately 24.8%, down from 44.3% in the same period of 2023[18] - The company reported a decrease in government grants received, totaling RMB 9,571,000 for the six months ended June 30, 2024, compared to RMB 15,108,000 in 2023, a decline of about 36.5%[24] - The company's profit decreased from RMB 89.5 million for the six months ended June 30, 2023, to a loss of RMB 172.2 million for the six months ended June 30, 2024, resulting in a net profit margin drop from 8.8% to -20.3%[66] Assets and Liabilities - The company's total assets as of June 30, 2024, were RMB 8,559,794 thousand, compared to RMB 8,281,041 thousand as of December 31, 2023[6] - Non-current assets increased to RMB 4,168,390 thousand as of June 30, 2024, from RMB 2,905,192 thousand at the end of 2023[5] - Current liabilities decreased to RMB 5,492,884 thousand as of June 30, 2024, from RMB 7,121,967 thousand at the end of 2023[5] - The company's total liabilities as of June 30, 2024, were RMB 1,938,946,000, down from RMB 2,065,701,000 as of December 31, 2023, reflecting a decrease of approximately 6.1%[21] - Trade receivables, net of loss provisions, amounted to RMB 202,397,000 as of June 30, 2024, slightly down from RMB 206,014,000 as of December 31, 2023[35] - Trade payables increased to RMB 64,587,000 as of June 30, 2024, compared to RMB 43,323,000 as of December 31, 2023[37] - As of June 30, 2024, cash and cash equivalents were RMB 2,158.2 million, a decrease of 24.6% from RMB 2,862.9 million as of December 31, 2023[68] - The capital debt ratio remained relatively stable at 18.1% as of June 30, 2024, compared to 17.4% as of December 31, 2023[69] Operational Developments - The company has a professional service team of 2,585 employees as of June 30, 2024, reflecting ongoing investment in talent development[40] - The construction of the Suzhou Zhaoyan Phase II facility, covering 20,000 square meters, has been topped out in 2023 and is expected to be operational by early 2025, enhancing business throughput and performance growth[41] - A new 22,000 square meter supporting facility in Suzhou is under renovation and is projected to be completed and operational by the end of 2024, aimed at providing a better working environment for employees[41] - The wholly-owned subsidiary Guangxi Weimei Biotechnology Co., Ltd. plans to initiate the construction of a non-human primate model animal testing facility in the second half of 2024, focusing on enhancing animal welfare[42] - The company successfully passed the FDA GLP inspection for its Beijing facility in the first half of 2024, marking the fifth successful inspection for both the Beijing and Suzhou facilities, ensuring compliance with international GLP standards[43] - The company has developed and optimized various ophthalmic disease models, including laser-induced mouse models and rabbit autoimmune uveitis models, to meet diverse market research needs[43] - The company has improved various drug administration methods for central nervous system drugs, establishing long-term catheter methods and verifying their effectiveness[45] - The company has established a high-level technical team of over 40 people for quality research and testing of innovative drugs, including protein drugs and gene therapy products[51] - The company has maintained a stable growth trend in the number of ongoing projects, with a total order amount of approximately RMB 2.9 billion, providing a guarantee for future performance[52] Strategic Initiatives - The company aims to enhance its non-clinical CRO business and expand upstream and downstream capabilities, including early drug discovery and clinical CRO services[71] - Plans to expand capacity include the completion of a 20,000 square meter facility in Suzhou, expected to be operational by early 2025[74] - The company intends to recruit more industry experts with overseas experience to strengthen its international business capabilities[73] - The company aims to expand its registration team to enhance international registration capabilities, addressing the growing demand for registrations[75] - The company plans to enhance its laboratory scale and team size for clinical testing, particularly in the U.S., to better support clinical trial needs[75] - The internationalization strategy includes supporting BIOMERE to expand its laboratory facilities in North America to increase service throughput[77] - The company will strengthen its business development team in the U.S. to enhance market promotion and leverage BIOMERE's brand reputation[77] Shareholder Information - The company did not recommend any interim dividend for the six months ended June 30, 2024, consistent with the previous year[33] - The company approved a dividend of RMB 0.16 per ordinary share for the 2023 profit distribution plan, to be paid in July 2024[33] - No interim dividend will be paid to shareholders for the six months ending June 30, 2024[80] Compliance and Governance - The company has adopted corporate governance codes in compliance with the Hong Kong Stock Exchange regulations[78] - The audit committee reviewed the interim financial results for the six months ended June 30, 2024, and confirmed compliance with relevant accounting standards[92]

证券代码：603127 证券简称：昭衍新药 公告编号：2024-042 北京昭衍新药研究中心股份有限公司 关于注销 2020 年股权激励计划第三个行权期已到期未行权股 票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京昭衍新药研究中心股份有限公司（以下简称"公司"）于 2024 年 8 月 30 日召开的第四届董事会第九次会议审议通过了《关于注销 2020 年股权激励计划第 三个行权期已到期未行权股票期权的议案》，现将相关事项说明如下： 一、 股权激励计划已履行的相关审批程序 1、2020 年 6 月 28 日，公司第三届董事会第十八次会议审议通过了《关于公 司<2020 年股票期权激励计划（草案）>及其摘要的议案》、《关于公司<2020 年股 票期权激励计划实施考核管理办法>的议案》、《关于提请股东大会授权董事会办理 股权激励相关事宜的议案》，公司第三届监事会第十一次会议审议通过上述议案。 公司已对激励对象名单在公司内部进行了公示，公示期满后，监事会对本次股权 激励计划授予激励对象名单进行了核查并对公示情况进 ...

北京昭衍新药研究中心股份有限公司 2024 年第二次独立董事专门会议决议 北京昭衍新药研究中心股份有限公司（以下简称"公司"或"昭衍新药"）2024 年第二次独立董事专门会议于 2024 年 8 月 30 日召开。本次会议应参加独立董事 4 人，实际参加独立董事 4 人。本次会议由独立董事孙明成先生主持。本次会议 的召集、召开及表决符合《中华人民共和国公司法》《上市公司独立董事管理办 法》及《北京昭衍新药研究中心股份有限公司章程》（以下简称"《公司章程》"） 的规定，会议程序合法、有效。 全体独立董事对公司第四届董事会第九次会议拟审议事项认真审议，会议形 成如下决议： 一、关于公司及子公司与其他关联方进行关联交易的审议意见 公司进行的关联交易均系日常经营及业务发展所需，交易定价按照市场价格 或成本加成定价，遵循了公开、公平、公正的原则，交易条款公平合理，且符合 股东整体利益，没有发现有损害本公司和非关联股东的行为和情况，符合相关法 律法规和《公司章程》的规定。我们同意将上述事项提交公司第四届董事会第九 次会议审议。 孙明成 翟永功 欧小杰 张 帆 北京昭衍新药研究中心股份有限公司 2024 年 8 月 30 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-040 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）及公司 指定信息披露媒体《上海证券报》披露的《北京昭衍新药研究中心股份有限公司 2024 年半年度报告》及其摘要。 2.审议通过《关于注销 2020 年股权激励计划第三个行权期已到期未行权股 票期权的议案》 经审核，监事会认为本次注销公司 2020 年股权激励计划第三个行权期已到 期未行权的股票期权，符合《股权激励管理办法》《股权激励计划》等关于股权 激励计划所涉相关权益注销的规定，股票期权注销的原因、数量合法、有效，不 存在损害公司及全体股东利益的行为。监事会同意注销上述股票期权共计 81.8888 万份。 北京昭衍新药研究中心股份有限公司 第四届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京昭衍新药研究中心股份有限公司（以下简称"公司"）第四届监事会第八 次会议于 2024 年 8 月 16 日以书面送达、电子邮件、电话等方式发出会议通知， 并于 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603127 证券简称：昭衍新药 公告编号：2024-039 北京昭衍新药研究中心股份有限公司 第四届董事会第九次会议决议公告 北京昭衍新药研究中心股份有限公司（以下简称"公司"或"昭衍新药"）第四 届董事会第九次会议于 2024 年 8 月 16 日以书面送达、电子邮件、电话等方式发 出会议通知，并于 2024 年 8 月 30 日在公司会议室以现场和电话会议相结合的形 式召开。本次会议应参加董事 9 人，实际参加董事 9 人，会议由董事长冯宇霞女 士主持；公司全体监事和部分高级管理人员列席会议。会议的召集和召开及表决 符合《中华人民共和国公司法》和《北京昭衍新药研究中心股份有限公司章程》 （以下简称"《公司章程》"）的规定，会议程序合法、有效。 本次会议经与会董事认真审议，以举手表决方式作出了如下决议： 1.审议通过《关于公司 2024 年半年度报告全文及摘要的议案》 表决结果：董事会以 9 票赞成、0 票反对、0 票弃权的表决结果通过该议案。 上述议案已经公司董事 ...